Incysus Therapeutics receives US patent for its technology

Biopharma company Incysus Therapeutics has been issued a patent by the U.S. Patent and Trademark Office for “Drug Resistant Immunotherapy for treatment of a cancer.”  According to the company, the patent covers the treatment of brain cancer with the combination of certain chemotherapies and a T cell genetically modified to confer chemotherapy resistance.  According to the company, Incysus has two Investigational New Drug applications (INDs) approved by the U.S. Food and Drug Administration…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news